Rewiring immunity: CAR-T cells as a paradigm shift in hematologic oncology.

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Hematologic malignancies represent a major US public health issue, impacting over 1.5 million people.
• While chemotherapy is standard, novel treatments like CAR T-cell therapy are revolutionizing care.

Purpose of the Study:

• To review the development, mechanism, applications, and barriers of CAR T-cell therapy.
• To provide clinicians with updated information on CAR T-cell therapy outcomes, toxicities, and access challenges.

Main Methods:

• Literature search of major biomedical databases.
• Focus on current clinical implementation of CAR T-cell therapies.

Main Results:

• Seven CAR T-cell therapies are FDA-approved for B-cell lymphoma, multiple myeloma, and acute lymphoblastic leukemia.
• These therapies demonstrate high response rates and effective malignant cell clearance.
• Significant challenges include manufacturing, geographic access, and high financial costs.

Conclusions:

• CAR T-cell therapy offers a powerful new approach to treating hematologic cancers.
• Addressing manufacturing, access, and cost barriers is crucial for equitable patient care.